Results 191 to 200 of about 305,001 (288)

Homoharringtonine suppresses acute myeloid leukemia progression by orchestrating EWSR1 phase separation in an m6A‐YTHDF2‐dependent mechanism

iMeta, EarlyView.
Homoharringtonine (HHT), a clinically approved anti‐leukemic drug, directly binds the RNA‐binding protein EWSR1. HHT induces an allosteric conformational switch in the RNA recognition motif of EWSR1, driving self‐association and liquid–liquid phase separation (LLPS). The resulting condensates act as regulatory hubs that sequester the m6A reader YTHDF2,
Ting‐Ting Liu, Li‐Ting Chen, Xu‐Ying Pei, Shao‐Nan Hu, Fang‐Fang Zhuo, Ze‐Kun Chen, Yang Liu, Jing‐Kang Wang, Ji‐Chao Zhang, Qi Cao, Ling Li, Jing Wang, Tian‐Tian Wei, Bo Han, Peng‐Fei Tu, Xiang‐Yu Zhao, Ruidong Xue, Ke‐Wu Zeng   +17 more
wiley   +1 more source

Genome‐wide CRISPR screen reveals an uncharacterized spliceosome regulator as new candidate immunotherapy target

iMeta, EarlyView.
This study identifies the uncharacterized gene C9ORF50 as a novel regulator of immune evasion. Functioning as an intrinsically disordered protein, C9ORF50 drives liquid‐liquid phase separation to facilitate spliceosome assembly and maintain RNA splicing fidelity.
Tong Shao, Chuanyang Liu, Jingyu Kuang, Sisi Xie, Ying Qu, Yingying Li, Lulu Zhang, Fangzhou Liu, Yanhua Qi, Tao Hou, Ming Li, Sujuan Zhang, Yu Liu, Zhixiang Yuan, Jiali Liu, Yanming Hu, Jingyang Wang, Chenghu Song, Shaowei Zhang, Lingyun Zhu, Jianzhong Shao, Aifu Lin, Wenjun Mao, Guangchuan Wang, Lvyun Zhu   +24 more
wiley   +1 more source

Most costly and prevalent reasons for hospitalization in children with medical complexity in Ontario, Canada

Journal of Hospital Medicine, EarlyView.
Abstract Background and Objectives Children with medical complexity (CMC) have chronic health conditions often associated with functional limitations. CMC comprise 1%–5% of the pediatric population. In Canada, their care accounts for one‐third of pediatric health spending.
Erin Hessey, Thaksha Thavam, Sanjay Mahant, Eyal Cohen, Jingqin Zhu, Francine Buchanan, Teresa To, Peter J. Gill, Ontario Pediatric Hospital Care Study Group (OPHCSG) and the Canadian Paediatric Inpatient Research Network (PIRN), Wenjia Chen, Ronald Cohn, Mairead Green, Matt Hall, Kate Langrish, Colin Macarthur, Myla Moretti, Patricia Parkin, Michelle Quinlan, Ann Bayliss, Ronik Kanani, Sean Murray, Catherine Pound, Mahmoud Sakran, Anupam Sehgal, Sepi Taheri, Gita Wahi   +25 more
wiley   +1 more source

Atypical Wounds in Chronic Graft‐Versus‐Host Disease and Peripheral Arterial Disease Caused by Tyrosine Kinase Inhibitors

JEADV Clinical Practice, EarlyView.
ABSTRACT The term “atypical wounds” primarily refers to lesions with immunological or cancerous etiologies. However, these wounds can also be drug‐induced. We report about a 32‐year‐old man with a 6‐year history of chronic myelogenous leukemia (CML) and chronic graft‐versus‐host disease (cGvHD) following an HLA‐compatible allogeneic stem cell ...
E. K. Stuermer, K. Malik, C. Willers, M. Augustin   +3 more
wiley   +1 more source

Real-world treatment and utilization of venetoclax for incident acute myeloid leukemia in a Medicare population. [PDF]

Future Oncol
Roth JA, D'Amico PG, Cappelleri JC, Donckels EA, Yu A, Okunev I, Petrilla A, Purcell S, Ma J, Russell A.   +9 more
europepmc   +1 more source

Dupilumab and Systemic Hematologic Malignancies: Case Series and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 15%–20% of children and 3%–10% of adults. An increased risk of systemic lymphomas – but not leukemias – has been reported in patients with AD. Dupilumab, a monoclonal IgG4 antibody targeting IL‐4 and IL‐13 signaling, is approved for moderate‐to‐severe AD and is ...
Nello Tommasino, Cataldo Patruno, Francesca di Vico, Maddalena Napolitano   +3 more
wiley   +1 more source

Acute Undifferentiated Leukemia Presented With Mediastinal Sarcoma. [PDF]

J Hematol
Alsoukhni H, Al-Dabbas D, Masalha M, Shkaibi O, Aljbour W, Obedat M.   +5 more
europepmc   +1 more source

Vitexin Attenuates the Growth and Glycolysis of Acute Myeloid Leukemia Cells by Suppressing the HIF‐1α‐Modulated YAP Pathway Under Hypoxic Conditions

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Vitexin, an apigenin flavone glycoside, exhibits antitumor activity against various cancers including leukemia. Hypoxia enhances glycolysis, thereby promoting tumor growth. In this study, we aimed to explore the effects of vitexin on hypoxia‐induced growth and glycolysis in acute myeloid leukemia (AML) cells and determine the underlying ...
Ping Wang, Jia‐Jia Zhang, Fang Zhang, Xiao‐Jie Qu, Hui Zhang   +4 more
wiley   +1 more source

Causal Effects of Plasma Metabolites on Leukemia: A Mendelian Randomization Study. [PDF]

Metabolites
Huang C, Li Y, Li M, Ye X, Wang T, Liu N, Meng X, Gao Y, Wang X.   +8 more
europepmc   +1 more source

The Global Burden of Leukemia, 1990–2021: A Systematic Analysis of Prevalence, DALYs, and Risk Factors From the Global Burden of Disease Study

Med Research, EarlyView.
Using data from the Global Burden of Disease Study 2021, we systematically assessed leukemia prevalence and disability‐adjusted life years (DALYs) across 204 countries and territories from 1990 to 2021, stratified by subtype, demographics, and risk factors.
Yuping Wu, Haini Zhang, Shuang Luo, Xiangmei Zhang, Mei Tan, Jinmei Chen, Pei Huang, Yan Chen, Zuochen Du   +8 more
wiley   +1 more source